Board of Directors

Peter Høngaard Andersen

Chairman of the Board, Scandion Oncology and member of board of directors since June 2019.

Holds a degree in Chemistry, Biochemistry and medicine.
Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and corporate patents.
Founder of Innovation Fund Denmark and Managing Director until May 2019 and chairing Innovative Medicines Initiative (IMI) from 2009 – 2014.
Co-founder of e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
53.065 shares and 80.377 warrants

 

Jørgen Bardenfleth

Vice-Chairman of the Board, Scandion Oncology and member of board of directors since 2018.
Chairman of the Board in Lyngsoe Systems, Dubex, Symbion and Impero.
Boardmember in Bizbrains, Minerva, Accelerace, BLOXHUB (vice chair), et al.

Jørgen holds a Master of Science degree in Engineering from the Technical University of Denmark (DTU, 1980) and a Master of Business Administration degree from the University of California at Los Angeles (UCLA, 1989).

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
410.629 shares and 53.585 warrants (Partly owned via Lioneagle ApS)

Carl Borrebäck

Member of the board of directors since 2018.
D.Sc, PhD.
Professor Lund University.
Co-founder of Immnovia AB, Senzagen AB, BioInvent International AB, Alligator BioScience AB.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
112.165 shares and 26.792 warrants (Partly owned via CB Ocean Capital AB)

Christian Vinding Thomsen

Member of the board of directors since 2017.
Partner, Bech-Bruun Law Firm.
Life Science specialist (M&A and regulatory).
Professional board member.

Christian holds a law degree (Cand.jur.) from the University of Copenhagen’s Faculty of Law.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
26.792 warrants

Thomas Feldthus

Member of the board of directors since 2018.
CEO of Fertilizer Invest ApS (M.Sc., MBA).
Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants
18.182 shares and 26.792 warrants

Bo Rode Hansen
President & Chief Executive Officer

Member of the board of directors since May 2020

MSc, Ph.D., MBA
Previously: President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (acquired by Roche).

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.

Scandion Oncology shares and warrants
25.173 shares and 1.071.688 warrants

Annie Rasmussen

Employee elected. Member of the board of directors since 2020.

RN, Master of Public Health

Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982. Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operation Oncology Venture A/S. Founder of HealthCreationDK and CancerGuidesDK. Board Member of North Star Group A/S. CCO & Member of the Management Team in Scandion Oncology A/S.

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.

Scandion Oncology shares and warrants
Please see under Management

Pipeline

Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance. 

Clinical Trials

Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Investors

Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.

We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.